Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Colin R. Simpson; Steven Kerr; Srinivasa Vittal Katikireddi; Colin McCowan; Lewis D. Ritchie; Jiafeng Pan; Sarah J. Stock; Igor Rudan; Ruby S. M. Tsang; Simon de Lusignan; F. D. Richard Hobbs; Ashley Akbari; Ronan A. Lyons; Chris Robertson; Aziz Sheikh

doi:10.1038/s41467-022-32264-6

Nature Communications (Aug 2022)

Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Colin R. Simpson,
Steven Kerr,
Srinivasa Vittal Katikireddi,
Colin McCowan,
Lewis D. Ritchie,
Jiafeng Pan,
Sarah J. Stock,
Igor Rudan,
Ruby S. M. Tsang,
Simon de Lusignan,
F. D. Richard Hobbs,
Ashley Akbari,
Ronan A. Lyons,
Chris Robertson,
Aziz Sheikh

Affiliations

Colin R. Simpson: School of Health, Wellington Faculty of Health, Victoria University of Wellington
Steven Kerr: Usher Institute, The University of Edinburgh
Srinivasa Vittal Katikireddi: Public Health Scotland
Colin McCowan: School of Medicine, University of St Andrews
Lewis D. Ritchie: Centre of Academic Primary Care, University of Aberdeen
Jiafeng Pan: Department of Mathematics and Statistics, University of Strathclyde
Sarah J. Stock: Usher Institute, The University of Edinburgh
Igor Rudan: Usher Institute, The University of Edinburgh
Ruby S. M. Tsang: Nuffield Department of Primary Care Health Sciences, University of Oxford
Simon de Lusignan: Nuffield Department of Primary Care Health Sciences, University of Oxford
F. D. Richard Hobbs: Nuffield Department of Primary Care Health Sciences, University of Oxford
Ashley Akbari: Population Data Science, Swansea University
Ronan A. Lyons: Population Data Science, Swansea University
Chris Robertson: Public Health Scotland
Aziz Sheikh: Usher Institute, The University of Edinburgh

DOI: https://doi.org/10.1038/s41467-022-32264-6
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 7

Abstract

Read online

Here, Simpson et al. analyze data from 3.6 million COVID-19 vaccine second doses (ChAdOx1 and BNT162b2) in Scotland for risk of thrombocytopenic, thromboembolic and hemorrhagic events. Borderline increased risks of immune thrombocytopenic purpura and cerebral venous sinus thrombosis were found for the ChAdOx1 vaccine. These events were rare and usually short-lived.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal